The application value of PET/CT evaluation standard PERCIST in the treatment of invasive non-Hodgkin's lymphoma

To explore the application value of PET/CT evaluation standard PERCIST in the treatment of invasive non-Hodgkin's lymphoma. From June 2017 to December 2018, 30 patients with pathological confirmed invasive non-Hodgkin's lymphoma were enrolled, and all of them received ¹⁸F-FDG PET/CT scans before and after therapy. Then all the patients received RECIST1.1, PERCIST1.0 and EORTC to evaluate the therapeutic efficacy, respectively. For the invasive nonhodgkins lymphoma, there was a poor agreement in response classification both between RECIST1.1 and PERCIST1.1 and between RECIST1.1 and EORTC. There was a good agreement in response control rate between all of them while the response rate according to the RECIST criteria was significantly lower than according to the EORTC and PERCIST criteria. There was a significant difference between response rate of RECIST criteria (which based on anatomical structure) and EORTC, PERCIST criteria(both of which based on metabolite) for response evaluation in patients with invasive nonhodgkins lymphoma treated with chemotherapy. Compared to EORTC standard, PERCIST1.0 with SULpeak as the main index is more accurate and reliable. (author)